Literature DB >> 7767905

Relationship between bcl-2 and myc gene expression in human neuroblastoma.

N Ikegaki1, M Katsumata, Y Tsujimoto, A Nakagawara, G M Brodeur.   

Abstract

We have investigated the relationship between the expression of bcl-2 and myc family genes in primary human neuroblastoma (NB) tumors and cell lines. Of 20 NB tumors examined, bcl-2 transcripts were expressed at variable levels in 16 tumors of all clinical stages. Of the 2 tumors with N-myc amplification, one expressed bcl-2 at a high level, whereas the other did so at a low level. In contrast, all NB tumors showed the expression of c-myc and/or N-myc transcripts. Similarly, of 9 NB cell lines with N-myc amplification examined, 6 expressed bcl-2 at high levels, whereas the other 3 expressed it at barely detectable levels. The 3 cell lines without N-myc amplification also expressed bcl-2 protein at high levels. All NB cell lines tested expressed either c-myc or N-myc protein. These data suggest that in NB, there is no significant association between bcl-2 expression and advanced tumor stages or N-myc amplification. The data also show that bcl-2 expression does not always coincide with myc expression in NB, suggesting that bcl-2- independent mechanisms may exist in the bcl-2-negative NB tumor cells in order to suppress the cell death promoting action of high myc expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7767905     DOI: 10.1016/0304-3835(95)03746-j

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

1.  Bcl-2 and M-Myc coexpression increases IGF-IR and features of malignant growth in neuroblastoma cell lines.

Authors:  R Jasty; C van Golen; H J Lin; G Solomon; K Heidelberger; P Polverini; A Opipari; E Feldman; V P Castle
Journal:  Neoplasia       Date:  2001 Jul-Aug       Impact factor: 5.715

Review 2.  The connections between neural crest development and neuroblastoma.

Authors:  Manrong Jiang; Jennifer Stanke; Jill M Lahti
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

3.  Novel therapeutic approaches for small cell lung cancer: the future has arrived.

Authors:  Maria Catherine Pietanza; Charles M Rudin
Journal:  Curr Probl Cancer       Date:  2012-04-10       Impact factor: 3.187

4.  Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.

Authors:  Charles M Rudin; Christine L Hann; Edward B Garon; Moacyr Ribeiro de Oliveira; Philip D Bonomi; D Ross Camidge; Quincy Chu; Giuseppe Giaccone; Divis Khaira; Suresh S Ramalingam; Malcolm R Ranson; Caroline Dive; Evelyn M McKeegan; Brenda J Chyla; Barry L Dowell; Arunava Chakravartty; Cathy E Nolan; Niki Rudersdorf; Todd A Busman; Mack H Mabry; Andrew P Krivoshik; Rod A Humerickhouse; Geoffrey I Shapiro; Leena Gandhi
Journal:  Clin Cancer Res       Date:  2012-04-11       Impact factor: 12.531

5.  Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification.

Authors:  Loen M Hansford; Wayne D Thomas; Joanna M Keating; Catherine A Burkhart; Anne E Peaston; Murray D Norris; Michelle Haber; Patricia J Armati; William A Weiss; Glenn M Marshall
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-16       Impact factor: 11.205

6.  Spatial association of apoptosis-related gene expression and cellular death in clinical neuroblastoma.

Authors:  J C Hoehner; C Gestblom; L Olsen; S Påhlman
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Morphological and molecular assessment of apoptotic mechanisms in peripheral neuroblastic tumours.

Authors:  S Uccini; C Colarossi; S Scarpino; R Boldrini; P G Natali; M R Nicotra; F M Perla; O Mannarino; P Altavista; C Boglino; C A Cappelli; D Cozzi; A Donfrancesco; G Kokai; P D Losty; H P McDowell; C Dominici
Journal:  Br J Cancer       Date:  2006-06-06       Impact factor: 7.640

8.  Apoptotic cell death in neuroblastoma.

Authors:  Yuanyuan Li; Akira Nakagawara
Journal:  Cells       Date:  2013-06-20       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.